Alpha Paradigm Partners, LLC Arcus Biosciences, Inc. Transaction History

Alpha Paradigm Partners, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$17.23 - $37.73 $1.15 Million - $2.51 Million	-66,508 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$28.92 - $41.83 $1.92 Million - $2.78 Million	66,508 New	66,508 $2.1 Billion
Q4 2021 Feb 14, 2022	SELL	$31.38 - $48.47 $1.69 Million - $2.61 Million	-53,910 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$26.93 - $37.68 $485,844 - $679,784	-18,041 Reduced 25.07%	53,910 $1.88 Billion
Q2 2021 Aug 13, 2021	BUY	$22.75 - $35.77 $1.64 Million - $2.57 Million	71,951 New	71,951 $1.98 Billion

196

51.7M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $931M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Alpha Paradigm Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Paradigm Partners, LLC with notifications on news.